Bio-Techne Corp (STU:TE1)
€ 69.5 0 (0%) Market Cap: 11.07 Bil Enterprise Value: 11.27 Bil PE Ratio: 80.74 PB Ratio: 5.63 GF Score: 95/100

Bio-Techne Corp at Bank of America Merrill Lynch Health Care Conference Transcript

May 15, 2019 / 09:20PM GMT
Release Date Price: €43.41 (+3.08%)
Michael Leonidovich Ryskin
BofA Merrill Lynch, Research Division - Associate

To kick off our next session, we're joined by Bio-Techne. I'm Mike Ryskin on the life science tools and diagnostics team here on behalf of Derek Brown. I think we're going to start with a quick intro presentation then we'll do a little bit of fireside chat but also we can open up to the audience for questions so...

James T. Hippel
Bio-Techne Corporation - Senior VP of Finance & CFO

Great. So I'm Jim Hippel, the CFO of Bio-Techne. I see some familiar faces in here but I also see some unfamiliar ones. So I'm not going to spend a ton of time describing the company, but I will spend just a few minutes here to get everyone on the same page.

Bio-Techne is essentially a 40-year-old-plus company that is a life science tools reagent provider and a world leader manufacturer of proteins, antibodies, assay kits and controls for diagnostic instruments. Roughly 5 or 6 years ago, a new CEO, Chuck Kummeth, came in and basically [continues] -- worked on a strategy with the company to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot